<DOC>
	<DOCNO>NCT02008734</DOCNO>
	<brief_summary>This Phase II study try identify whether short term treatment PD0332991 yield anti-proliferative response -defined low level Ki67 expression ( IHC ) surgery- induces senescence determine SABG expression ( IHC ) tumor patient early breast cancer non-candidates neoadjuvant hormonotherapy chemotherapy , compare treatment .</brief_summary>
	<brief_title>Randomized Phase II Study Assess PD 0332991 Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Female patient age 18 year old . 3 . Histologically cytologically confirm untreated invasive carcinoma breast irrespective HER2 ER status 4 . No personal history breast cancer within last 5 year 5 . Candidates initial breast surgery , minimum size 15 mm measure breast US . Bilateral multifocal tumor allow , assume tumor evaluation pre posttreatment biopsy perform target lesion . 7 . High proliferative tumor define either Grade 3 Ki67 ≥20 % 8 . No evidence metastatic disease . 9 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0/1 . 10 . Left ventricular ejection fraction ( LVEF ) least 50 % 11 . Negative pregnancy test woman childbearing potential within 14 day prior treatment initiation ( premenopausal le 12 month amenorrhea postmenopause , undergone surgical sterilization ) . 12 . For woman childbearing potential sexually active , agreement use highly effective , nonhormonal form contraception two effective form nonhormonal contraception least 6 month posttreatment . 13 . Patients must affiliate social security system 1 . Patients noncandidate upfront breast surgery candidate neoadjuvant chemotherapy hormonotherapy . 2 . Patients previously treat breast cancer last 5 year receive another concomitant anticancer treatment like chemotherapy , immunotherapy , endocrine 4 . Known hypersensibility PD0332991 component . 5 . Difficulty swallow oral medication 6 . Serious uncontrolled concomitant disease would put patient high risk treatmentrelated complication . 7 . Patient whose general clinical condition consider postpone surgery 8 . Inadequate organ function , evidence follow laboratory result : Absolute neutrophil count &lt; 1,500 cells/mm3 Platelet count &lt; 100,000 cells/mm3 Hemoglobin &lt; 9 g/dL Total bilirubin great 1,5 time upper limit normal ( ULN ) ( unless patient document Gilbert 's syndrome ) Aspartate aminotransferase ( AST [ SGOT ] ) alanine aminotransferase ( ALT [ SGPT ] ) &gt; 2.5 x ULN Serum creatinine &gt; 2.0 mg/dL and/or 177 μmol/L clearance creatinine &lt; 50mL/min ( calculate CockcroftGault method ) International normalize ratio ( INR ) activate partial thromboplastin time ( aPTT ) partial thromboplastin time ( PTT ) &gt; 1.5 x ULN ( unless therapeutic coagulation ) 9 . Uncontrolled hypertension ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) clinically significant ( i.e . active ) cardiovascular disease : cerebrovascular accident/stroke myocardial infarction within 6 month prior first study medication ; unstable angina ; CHF New York Heart Association ( NYHA ) Grade II high ; serious cardiac arrhythmia require medication . 10 . Patients history longQT syndrome document family history longQT syndrome . 11 . QTc &gt; 470 12. serum potassium level &lt; LLN 13 . Uncontrolled intercurrent illness include limited , know active infection human immunodeficiency virus ( HIV ) , hepatitis B C virus psychiatric illness/social situation would limit compliance study requirement . 14 . Assessed investigator unable unwilling comply requirement protocol . 15 . Pregnant breastfeeding patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>